Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleINFLAMMATION, IMMUNOPHARMACOLOGY, AND ASTHMA

Regulation of Lipopolysaccharide-Induced Inducible Nitric-Oxide Synthase Expression through the Nuclear Factor-κB Pathway and Interferon-β/Tyrosine Kinase 2/Janus Tyrosine Kinase 2-Signal Transducer and Activator of Transcription-1 Signaling Cascades by 2-Naphthylethyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline (THI 53), a New Synthetic Isoquinoline Alkaloid

Hye Jung Kim, Konstantin Tsoyi, Ja Myung Heo, Young Jin Kang, Min Kyu Park, Young Soo Lee, Jae Heun Lee, Han Geuk Seo, Hye Sook Yun-Choi and Ki Churl Chang
Journal of Pharmacology and Experimental Therapeutics February 2007, 320 (2) 782-789; DOI: https://doi.org/10.1124/jpet.106.112052
Hye Jung Kim
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Konstantin Tsoyi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ja Myung Heo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Young Jin Kang
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Min Kyu Park
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Young Soo Lee
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jae Heun Lee
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Han Geuk Seo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hye Sook Yun-Choi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ki Churl Chang
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

The effects of 2-naphthylethyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline (THI 53), on nitric oxide (NO) production and inducible nitric-oxide synthase (iNOS) protein induction by lipopolysaccharide (LPS) were investigated in RAW 264.7 cells and mice. In cells, THI 53 concentration dependently reduced NO production and iNOS protein induction by LPS. In addition, THI 53 inhibited NO production and iNOS protein induction in LPS-treated mice. LPS-mediated iNOS protein induction was inhibited significantly by the specific tyrosine kinase inhibitor α-cyano-(3-hydroxy-4-nitro)cinnamonitrile (AG126) as well as by THI 53. In addition, a c-Jun NH2-terminal kinase (JNK) inhibitor anthra[1,9-cd]pyrazole-6 (2H)-one) (SP600125) but not an extracellular regulated kinase inhibitor [2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one (PD98029)] or a p38 inhibitor [4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)1H-imidazole (SB230580)] reduced the iNOS protein level induced by LPS. Moreover, a Janus kinase 2 (JAK2) inhibitor α-cyano-(3,4-dihydroxy)-N-benzylcinnamide (AG490) dose-dependently prevented LPS-mediated iNOS protein induction. LPS activated phosphorylations of tyrosine kinases, especially tyrosine kinase 2 (Tyk2) and signal transducer and activator of transcription-1 (STAT-1); these were reduced by THI 53. LPS also phosphorylated the JNK pathway; however, this phosphorylation was unaffected by THI 53. Interestingly, a JNK inhibitor (SP600125) and another tyrosine kinase inhibitor (genistein) significantly inhibited STAT-1 phosphorylation, suggesting that the LPS-activated JNK pathway and a tyrosine kinase pathway (especially Tyk2) may link to the STAT-1 pathway, which is involved in iNOS induction. However, THI 53 regulates LPS-mediated iNOS protein induction by affecting the Tyk2/JAK2-STAT-1 pathway, not the JNK pathway. The inhibition by THI 53 of LPS-induced NO production was recovered by a tyrosine phosphatase inhibitor (Na3VO4), which supports the possibility that THI 53 inhibits the LPS-induced inflammatory response through regulation of tyrosine kinase pathways. THI 53 also inhibited LPS-mediated interferon (IFN)-β production and nuclear factor-κB (NF-κB) activation. Thus, THI 53 may regulate LPS-mediated inflammatory response through both the NF-κB and IFN-β/Tyk2/JAK2-STAT-1 pathways.

Footnotes

  • This study was supported by the Korea Science and Engineering Foundation (R13-2005-005-01003-0).

  • H.J.K. and K.T. contributed equally to this work.

  • Article, publication date, and citation information can be found at http://jpet.aspetjournals.org.

  • doi:10.1124/jpet.106.112052.

  • ABBREVIATIONS: iNOS, inducible nitric-oxide synthase; NO, nitric oxide; LPS, lipopolysaccharide; NF-κB, nuclear factor-κB; MAPK, mitogen-activated protein kinase; ERK, extracellular regulated kinase; JNK, c-Jun N-terminal kinase; JAK, Janus protein tyrosine kinase; IκB, inhibitor of NF-κB; STAT, signal transducer and activator of transcription; Tyk2, tyrosine kinase 2; THI 53, 2-naphtylethyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline; AG490, α-cyano-(3,4-dihydroxy)-N-benzylcinnamide; AG126, α-cyano-(3-hydroxy-4-nitro)cinnamonitrile; SB203580, [4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)1H-imidazole]; PD98029, ·; ECL, enhanced chemoluminescence; SP600125 (anthra[1,9-cd]pyrazole-6 (2H)-one); MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium; NOx, nitrite; PVDF, polyvinylidene difluoride; BSA, bovine serum albumin; IFN, interferon; MAP, mitogen-activated protein; AP-1, activator protein-1; THI 52, 1-naphthylethyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline; TLR4, Toll-like receptor 4; PD98029, 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one.

  • ↵1 Current affiliation: Department of Pharmacology, College of Medicine, Yeungnam University, Daegu, Korea.

    • Received August 4, 2006.
    • Accepted November 13, 2006.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 385 (3)
Journal of Pharmacology and Experimental Therapeutics
Vol. 385, Issue 3
1 Jun 2023
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Regulation of Lipopolysaccharide-Induced Inducible Nitric-Oxide Synthase Expression through the Nuclear Factor-κB Pathway and Interferon-β/Tyrosine Kinase 2/Janus Tyrosine Kinase 2-Signal Transducer and Activator of Transcription-1 Signaling Cascades by …
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleINFLAMMATION, IMMUNOPHARMACOLOGY, AND ASTHMA

Regulation of Lipopolysaccharide-Induced Inducible Nitric-Oxide Synthase Expression through the Nuclear Factor-κB Pathway and Interferon-β/Tyrosine Kinase 2/Janus Tyrosine Kinase 2-Signal Transducer and Activator of Transcription-1 Signaling Cascades by 2-Naphthylethyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline (THI 53), a New Synthetic Isoquinoline Alkaloid

Hye Jung Kim, Konstantin Tsoyi, Ja Myung Heo, Young Jin Kang, Min Kyu Park, Young Soo Lee, Jae Heun Lee, Han Geuk Seo, Hye Sook Yun-Choi and Ki Churl Chang
Journal of Pharmacology and Experimental Therapeutics February 1, 2007, 320 (2) 782-789; DOI: https://doi.org/10.1124/jpet.106.112052

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleINFLAMMATION, IMMUNOPHARMACOLOGY, AND ASTHMA

Regulation of Lipopolysaccharide-Induced Inducible Nitric-Oxide Synthase Expression through the Nuclear Factor-κB Pathway and Interferon-β/Tyrosine Kinase 2/Janus Tyrosine Kinase 2-Signal Transducer and Activator of Transcription-1 Signaling Cascades by 2-Naphthylethyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline (THI 53), a New Synthetic Isoquinoline Alkaloid

Hye Jung Kim, Konstantin Tsoyi, Ja Myung Heo, Young Jin Kang, Min Kyu Park, Young Soo Lee, Jae Heun Lee, Han Geuk Seo, Hye Sook Yun-Choi and Ki Churl Chang
Journal of Pharmacology and Experimental Therapeutics February 1, 2007, 320 (2) 782-789; DOI: https://doi.org/10.1124/jpet.106.112052
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Population PK/PD analysis of sutimlimab
  • CCR6 selective antagonist in homeostasis and inflammation
  • PK/PD of Dexamethasone in LPS-Challenged Rats
Show more Inflammation, Immunopharmacology, and Asthma

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics